Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration

Rhea-AI Summary

Nutriband (NASDAQ: NTRB / NTRBW) announced a non-binding Letter of Intent dated Dec 18, 2025 to explore advanced technology collaboration with Qvanta Group of Companies.

The LOI contemplates joint evaluation of quantum‑ready AI simulation, secure high‑performance computing, and cybersecurity/data‑integrity frameworks to support Nutriband’s abuse‑deterrent pharmaceutical research and product development. The parties will emphasize regulatory compliance and data protection. The LOI is non‑binding and expressly states there is no assurance a definitive agreement or transaction will occur.

Key Figures

Quarter revenue $346,058 Quarter ended Oct 31, 2025; down from $645,796 prior-year quarter

Nine-month revenue $1.64M Nine months ended Oct 31, 2025; up from $1.50M

Nine-month net loss $7.26M Nine months ended Oct 31, 2025

Net loss to common $29.08M ($2.54/share) Nine months ended Oct 31, 2025 including $21.81M preferred dividend

Cash balance $5.31M As of Oct 31, 2025 per 10-Q

Working capital $5.04M As of Oct 31, 2025 per 10-Q

Public warrants 910,904 warrants Outstanding under 424B3 supplement, exercisable for common stock

Warrant exercise price $6.43 per share Exercise price for 910,904 public warrants (NTRBW)

Market Reality Check

$4.49 Last Close

Volume Volume 14,846 is at 0.63x the 20-day average of 23,416 shares. low

Technical Shares at $4.40, trading below the 200-day MA of $6.57 and 62.65% under the 52-week high.

Peers on Argus

Key biotech peers like CVM (-4.92%), OKYO (-5.18%) and STRO (-8.24%) were negative, but no peers appeared in the momentum scanner and no same-day peer news was flagged, suggesting this LOI is stock-specific rather than part of a sector-wide move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 24	Conference appearance	Positive	-2.1%	Announcement of Noble Capital emerging growth conference presentation and webcast access.
Oct 28	FDA interaction	Positive	+10.4%	FDA meeting minutes confirming 505(b)(2) NDA pathway and guidance for AVERSA FENTANYL.
Oct 27	Management change	Positive	-1.7%	Co‑founder Gareth Sheridan returning as CEO with focus on 2026 NDA filing.
Oct 10	Branding agreement	Positive	-5.1%	Brand Institute engaged to develop commercial name and identity for AVERSA FENTANYL.
Oct 08	IP strengthening	Positive	+8.4%	Provisional patent filing to enhance AVERSA transdermal abuse‑deterrent technology coverage.

Pattern Detected

Recent company-development news often saw mixed reactions, with some positive regulatory and IP updates aligning with price gains but several operational announcements coinciding with declines.

Recent Company History

Over the last few months, Nutriband focused on advancing its AVERSA™ abuse‑deterrent fentanyl patch and related corporate positioning. On Oct 8, it filed a provisional patent to enhance AVERSA technology, followed by an agreement with Brand Institute on Oct 10 for global branding work. Late October brought an FDA meeting update and CEO transition, including plans toward an NDA filing in 2026. A November announcement highlighted an investor conference appearance. Today’s LOI adds a prospective technology exploration layer around secure AI and quantum-enabled infrastructure for its abuse-deterrent portfolio.

Market Pulse Summary

This announcement outlines a non-binding LOI for Nutriband to explore secure AI, quantum-enabled simulation, and cybersecurity capabilities from Qvanta to support its abuse-deterrent transdermal portfolio. It does not create any immediate commercial arrangement or guaranteed transaction. In context, recent SEC filings show nine‑month revenue of $1.64M versus a net loss of $7.26M, plus outstanding public warrants. Investors may watch for any definitive agreements, regulatory milestones for AVERSA™, and updates on cash resources and operating losses.

Key Terms

transdermal medical

"a developer of transdermal pharmaceutical products including abuse-deterrent technologies"

Transdermal describes a method of delivering a drug through the skin so the active ingredient is absorbed into the bloodstream, commonly via a patch, gel or cream. For investors, transdermal delivery affects a product’s convenience, steady dosing, patent and regulatory profile, manufacturing needs and market appeal—similar to a slow-release battery that makes a device easier to use and last longer, which can influence sales potential and risk.

abuse-deterrent medical

"pharmaceutical products including abuse-deterrent technologies, today announced the signing"

A product described as abuse-deterrent is designed to make intentional misuse—such as crushing, dissolving or injecting—harder or less rewarding, often through physical barriers, additives that make tampering difficult, or properties that cause unpleasant effects if manipulated. For investors, such features can change a drug’s regulatory path, market acceptance, insurance coverage and legal risk, much like adding a safety lock can alter a product’s appeal, liability and sales potential.

quantum-ai technical

"developing the BigΔx Quantum Defense Fabric, an integrated quantum-AI cybersecurity"

Quantum-AI combines early-stage quantum computing hardware with artificial intelligence methods to solve problems that classical computers handle slowly or can't solve at all. Think of it as trying to give AI a supercharged engine that can explore many possibilities at once; for investors this matters because it could create new products, speed up research, or change competitive dynamics, but timelines, costs, and practical benefits remain uncertain.

cybersecurity technical

"Quantum Defense Fabric, an integrated quantum-AI cybersecurity and computing platform"

Cybersecurity involves protecting computers, networks, and digital information from theft, damage, or unauthorized access. It is essential for safeguarding sensitive data and maintaining trust in digital systems, which matters to investors because strong cybersecurity reduces the risk of costly breaches and disruptions that can impact a company’s performance and reputation. Think of it as locking and safeguarding valuable information much like securing a safe to prevent theft.

high-performance computing technical

"quantum-AI simulation capabilities, secure high-performance computing infrastructure, and advanced"

A cluster of very powerful computers, special chips and fast networks designed to tackle huge, complex calculations far faster than a normal PC — like replacing a single delivery van with a synchronized fleet to move a city’s worth of packages. For investors, high-performance computing matters because it enables faster product development, more accurate simulations and data analysis, and new revenue streams for hardware, software and services, making firms that supply or use it potentially more competitive and scalable.

weapon of mass destruction regulatory

"designating illicit fentanyl as a Weapon of Mass Destruction, recognizing the substance"

A weapon of mass destruction is an armament—nuclear, chemical, biological, or similarly devastating—that can kill or injure large numbers of people or cause widespread damage to infrastructure and the environment. For investors it matters because the use or threat of such weapons can rapidly reshape markets, prompt government intervention, disrupt supply chains and trade, and drive sudden shifts in asset prices and risk perception, much like a sweeping natural disaster that forces abrupt economic and policy changes.

artificial intelligence technical

"America’s AI Action Plan emphasizes accelerating the responsible adoption of artificial intelligence"

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

quantum information science technical

"Genesis Mission Executive Order establishes quantum information science as a national priority"

A field that studies how information can be stored, transmitted and processed using the strange behaviors of atoms and subatomic particles, then builds devices and software that exploit those behaviors. It matters to investors because it promises completely new ways to solve problems—like much faster searches, stronger encryption, and novel materials—so breakthroughs can create high-growth industries, render existing technologies obsolete, and require large long-term investments.

AI-generated analysis. Not financial advice.

The LOI Aligns with Federal Priorities on Fentanyl Crisis, Artificial Intelligence, and Quantum Technology

ORLANDO, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) ("Nutriband" or the "Company"), a developer of transdermal pharmaceutical products including abuse-deterrent technologies, today announced the signing of a non-binding Letter of Intent ("LOI") with the Qvanta Group of Companies.

The Qvanta Group comprises Qvanta LLC and its subsidiaries, Qvanta Foundry LLC and Qvanta Capital LLC (collectively, “Qvanta”). Qvanta is a U.S.-based advanced technology organization developing the BigΔx Quantum Defense Fabric, an integrated quantum-AI cybersecurity and computing platform designed to support enterprise, government, and high-security research environments.

The announcement comes amid heightened federal focus on three converging national priorities. On December 15, 2025 President Trump signed an Executive Order designating illicit fentanyl as a Weapon of Mass Destruction, recognizing the substance as a direct threat to U.S. national security (https://www.whitehouse.gov/presidential-actions/2025/12/designating-fentanyl-as-a-weapon-of-mass-destruction/).

In parallel, the Administration’s America’s AI Action Plan emphasizes accelerating the responsible adoption of artificial intelligence across regulated sectors, including healthcare and pharmaceuticals (https://www.whitehouse.gov/articles/2025/07/white-house-unveils-americas-ai-action-plan/).

Additionally, the Genesis Mission Executive Order establishes quantum information science as a national priority, underscoring the strategic importance of advanced computing technologies in addressing complex national challenges (https://www.whitehouse.gov/presidential-actions/2025/11/launching-the-genesis-mission/).

Nutriband believes that Qvanta’s quantum-AI simulation capabilities, secure high-performance computing infrastructure, and advanced cybersecurity technologies may provide meaningful support for Nutriband’s research, innovation efforts, and long-term product development initiatives.

Under the LOI, the parties plan to explore potential collaboration areas including secure AI and analytics platforms for regulated pharmaceutical data, cybersecurity and data-integrity frameworks that support abuse-deterrent technologies, and advanced modeling and simulation capabilities enabled by quantum-ready infrastructure. Any discussions would emphasize regulatory compliance, strong data protection, and responsible technology use.

The LOI is non-binding and does not establish a partnership, joint venture, equity investment, licensing arrangement, or other binding commercial relationship. Any future collaboration would be subject to additional technical and regulatory review, due diligence, and the execution of definitive agreements. There can be no assurance that a definitive agreement will be reached or that any transaction will ultimately occur.

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband's AVERSA™ technology directly addresses the fentanyl crisis by incorporating aversive agents into transdermal patches designed to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The Company's lead product under development is an abuse-deterrent fentanyl transdermal system, protected by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband Inc.

Nutriband Inc. (NASDAQ: NTRB) develops transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch incorporating proprietary AVERSA™ technology. For more information, visit www.nutriband.com.

About Qvanta Group of Companies

The Qvanta Group of Companies (https://qvanta.io) develops AI-driven and quantum-ready infrastructure solutions for national security, enterprise resilience, and regulated industries. The group comprises Qvanta LLC (operating entity), Qvanta Foundry LLC (R&D), and Qvanta Capital LLC (investment solutions).

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words "believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K's and Forms 10-Q's, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contact Information:

Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

SOURCE: Nutriband Inc.

FAQ

What did Nutriband (NTRB) announce on December 18, 2025?

Nutriband announced a non‑binding Letter of Intent with Qvanta Group to explore quantum‑AI, secure computing, and cybersecurity support for abuse‑deterrent pharmaceutical work.

Does the LOI between Nutriband (NTRB) and Qvanta create a binding partnership or investment?

No; the LOI is non‑binding and does not establish a partnership, joint venture, equity investment, license, or other binding commercial relationship.

What technology areas will Nutriband and Qvanta explore under the LOI?

The parties plan to explore secure AI and analytics for regulated pharmaceutical data, cybersecurity and data‑integrity frameworks, and quantum‑ready modeling and simulation capabilities.

Will the Nutriband LOI immediately affect NTRB stock or finances?

The announcement includes no financial terms or commitments and states there is no assurance a definitive agreement or transaction will occur.

What approvals or steps are required before Nutriband and Qvanta can collaborate?

Any future collaboration is subject to additional technical and regulatory review, due diligence, and execution of definitive agreements.

How does the LOI reference federal priorities including fentanyl, AI, and quantum technology?

The LOI is described as aligning with federal priorities called out in recent executive actions on fentanyl, America’s AI Action Plan, and a Genesis Mission on quantum information science.